

Signant SmartSignals® Solutions for  
Multiple Myeloma

# MAKING STRIDES TOWARDS NEW TREATMENTS **ONE STUDY AT A TIME**

The third most common blood cancer, multiple myeloma (MM) is a complex, dynamic disease. Survival rates have improved recently because of treatments that offer a chance at durable remission, but high-risk MM remains an area of urgent and unmet need. Signant Health applies decades of clinical oncology experience alongside our comprehensive research optimization solutions to help study teams deliver new therapies and treatments sooner.

## **OPTIMIZE PROM RELIABILITY & EXPEDITE STUDY START-UP**

Key endpoints in MM trials require reliable patient-reported outcome measurement (PROM) data. Signant's eCOA solution, optimized for oncology, includes a library of electronic, pre-validated oncology instruments that help patients provide complete, accurate, and timely responses, improving PRO accuracy compared to paper and pencil. In addition, launching studies faster can help expand the reach and impact of potential therapies and treatments. Our library of common study design templates helps sponsors and CROs launch quickly.

## **PREVENT WASTE AND REDUCE SHIPMENTS & RETURNS**

MM studies often involve multiple patient cohorts and complex dosing schedules. Another variable adding complexity, investigational products for these and other oncology studies can be expensive as well as limited in supply and shelf life.

Signant's RTSM system utilizes unique algorithms to implement complex randomization schemes rapidly and optimize lot usage and efficiency. We support your study with a project team of multidisciplinary clinical science and operations experts from launch to closeout.

Signant's end-to-end suite of evidence generation solutions and accompanying multiple myeloma clinical science and medicine expertise reduce burdens for participants and study teams while generating more accurate, reliable data.

## **INCREASE PATIENT COMPREHENSION AND EASE BURDENS FOR SITES & PATIENTS**

Patient-reported outcome measures (PROMs) are vital to fully evaluate MM treatment risk-benefit profiles. Our eCOA solution can be tailored to your protocol and patient population's needs – guided assessments and built-in edit checks reduce errors while alerts and reminders improve adherence to medication dosing schedules.

## **COLLECT MORE COMPLETE PATIENT FUNCTION DATA**

Help your study team collect accurate data about treatment effects on patient function. We integrate ActiGraph with our eCOA system to automatically collect sleep and activity data without imposing additional burdens on patients or sites. Study teams can view this data alongside COA data for a more complete evaluation of patient function.

## **DIGITIZE STUDIES FOR END-TO- END ACCURACY & VISIBILITY**

While all of our solutions can be used as standalone tools, when combined they enhance the accuracy and efficiency of your multiple myeloma study. Gain immediate access to electronic data for faster decision-making and improved regulatory inspections.

# SIGNANT'S MULTIPLE MYELOMA EXPERIENCE BY THE NUMBERS



I - III  
PHASES



90  
TRIALS



8,000  
SITES



22,000  
PATIENTS



57  
COUNTRIES



82  
LANGUAGES

## DRIVE BETTER RESEARCH OUTCOMES WITH SIGNANT SMARTSIGNALS SOLUTIONS

These solutions can be used individually or integrated together for a seamless, end-to-end digital experience.



eCOA

[LEARN MORE →](#)



RTSM

[LEARN MORE →](#)



TELEMEDICINE

[LEARN MORE →](#)



eCONSENT

[LEARN MORE →](#)




SENSORS &  
WEARABLES

[LEARN MORE →](#)

## DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



[MEET THE EXPERTS →](#)